



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1023-G)

PATENT

In re Application of:

B. Frank et al

Serial No.: 08/901,612

Filed: July 28, 1997

For: Oligonucleotides Specific for Hepatitis
B Virus

Asst. Commissioner for Patents
Washington, DC 20231

Group Art Unit: 1635

Examiner: T. Larson

41 / K.T.
1/25
F

RECEIVED

JAN 22 2002

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO THE JUNE 01, 2001 OFFICE ACTION

In response to the Office Action mailed June 1, 2001, please enter the following amendment and consider the following remarks.

AMENDMENT

In the Claims:

A marked-up version of the following amended claims is attached as Appendix A.

A clean copy of all the pending claims is attached as Appendix B.

Please amend claims 1, 8-20, 36 and 47 as follows:

1. A synthetic oligonucleotide complementary to a portion of the epsilon region of the HBV genome selected from the group consisting of SEQ ID NOS: 7-19 and 45, which oligonucleotide inhibits HBV replication.

8. The synthetic oligonucleotide of claim 1 wherein the oligonucleotide is SEQ ID NO: 7.

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 30 day of October, 2001.

John A. Ware